Healthcare
NeurAxis, Inc.(NRXS)
Live Price
Offline$7.15
+6.56% today
1Y Change
+177.13%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $90.00M
- Revenue Growth
- +32.9%
- EPS Growth
- +22.1%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
NeurAxis, Inc. (NRXS) is a Healthcare stock with a market cap of $90.00M and listed on AMEX. The stock last traded around $7.15 and up 177.1% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +32.9%, EPS growth of +22.1%, a dividend yield of 0.0%. What stands out right now is revenue +32.9%, EPS +22.1%, free cash flow -5.5% with operating margin -219.4% and ROIC -204.7%. Valuation already assumes a fairly strong business story at price/sales 26.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines NRXS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+32.9% vs +7.6% peer median
Operating Margin
Below sector median
-219.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 27, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +32.9% and EPS at +22.1%, with operating margin around -219.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 27, 2026 | โ | -2.1% | -5.1% | โ |
2026 Mar 19, 2026 | +20.9% | +6.4% | -2.2% | +0.8% |
2025 Nov 10, 2025 | โ | -5.9% | -9.8% | +5.5% |
Benchmark Edge
NRXS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NRXS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NRXS Max Drawdown
-39.53%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NRXS and SPY.
Company Overview
NeurAxis, Inc.
New York Stock Exchange American
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
- Leadership
- Brian Carrico
- IPO Date
- Aug 9, 2023
- Employees
- 21
- Street Address
- 11550 North Meridian Street
- Mailing
- Carmel, IN, 46032
- Region
- Carmel, IN, US
- Reporting Currency
- USD
- Investor Line
- (812) 689-0791
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 26.0
- Price/Book
- 21.6
Growth
- Revenue
- +32.9%
- EPS
- +22.1%
- Free Cash Flow
- -5.5%
Profitability
- Gross Margin
- 84.2%
- Operating Margin
- -219.4%
- Net Margin
- -218.5%
- ROE
- -306.0%
- ROIC
- -204.7%
Balance Sheet
- Debt/Equity
- 0.12
- Current Ratio
- 2.05
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.